PJSC Ozon Pharmaceuticals EBIT

The latest EBIT for OZPH.ME is $12B as of June 2026. That is below the sector sector average of $2.6T. Investors often review this figure alongside PJSC Ozon Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, OZPH.ME currently prints $12B for EBIT, while the sector average sits near $2.6T. That is roughly 99.5% below the sector mean. Large gaps often invite a closer look at PJSC Ozon Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $12B for OZPH.ME is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting OZPH.ME's EBIT ($12B), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.